Exchange: NASDAQ·Updated 07:59 PM EDT

BTCYBiotricity Inc

$0.4631
$0.1829
(28.31%)
Today
Closed $0.4631
$0.0232
(5.01%)
After Hours
EarningsAug 13
Mkt Cap$2.14M
Vol532,001.00
News
all
press releases
The Zacks Analyst Blog Highlights Hims & Hers Health, Biotricity and Privia Health
Hims & Hers leads three healthcare IT stocks up over 20% in 2025, as digital care, remote monitoring and data platforms gain traction.
Zacks
More News
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Zacks
Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates
Biotricity (BTCY) delivered earnings and revenue surprises of +62.50% and -0.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +6.90% and +104.82%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +15.00% and +4.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +158.33% and +3.47%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
Doximity (DOCS) delivered earnings and revenue surprises of +18.42% and +6.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
iRhythm Technologies (IRTC) Reports Q3 Loss, Beats Revenue Estimates
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of +83.33% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are Medical Stocks Lagging Biotricity (BTCY) This Year?
Here is how Biotricity Inc. (BTCY) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Zacks
Biotricity (BTCY) Upgraded to Buy: Here's Why
Biotricity (BTCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
<
1
2
...
>

Advertisement|Remove ads.